Effect of a homeopathic drug, Chelidonium, in amelioration of p-DAB induced hepatocarcinogenesis in mice

Biswas, Surjyo Jyoti; Khuda-Bukhsh, Anisur Rahman

doi:10.1186/1472-6882-2-4

BMC Complementary Medicine and Therapies

Table 3 Mean activities of lipid peroxidase (nMol MDA/gm wet tissue), acid and alkaline phosphatase activities (in terms of mM Phenol liberated/100 mg protein after 30 min of incubation at 37°C), in different organs of mice treated with p Dimethylaminoazobenzene (DAB) + Phenobarbital (PB), DAB + PB + Chelidonium (Ch)-30 and DAB + PB + Chelidonium (Ch)-200 against their normal and phenobarbital control.

From: Effect of a homeopathic drug, Chelidonium, in amelioration of p-DAB induced hepatocarcinogenesis in mice

		Lipid peroxidase activity						Alkaline phosphatase activity						Acid phosphatase activity
Fixation Interval (Days)	Series	Liver		Kidney		Spleen		Liver		Kidney		Spleen		Liver		Kidney		Spleen
		Activity ± SE	% Prot.	Activity ± SE	% Prot.	Activity ± SE	% Prot.	Activity ± SE	% Prot.	Activity ± SE	% Prot.	Activity ± SE	% Prot.	Activity ± SE	% Prot.	Activity ± SE	% Prot.	Activity ± SE	% Prot.
	Normal	18.72 ± 1.27		16.67 ± 0.26		25.44 ± 0.68		0.09 ± 0.01		0.12 ± 0.03		0.09 ± 0.01		0.10 ± 0.002		0.09 ± 0.004		0.10 ± 0.003
	PB	16.58 ± 0.43		15.85 ± 1.39		17.35 ± 0.45		0.11 ± 0.001		0.11 ± 0.004		0.11 ± 0.002		0.18 ± 0.02		0.15 ± 0.02		0.15 ± 0.02
60	DAB +PB	117.48 ± 3.80		134.41 ± 1.08		207.95 ± 3.01		0.28 ± 0.04		0.25 ± 0.02		0.15 ± 0.01		0.30 ± 0.03		0.29 ± 0.05		0.27 ± 0.04
	DAB+PB+Ch30	24.26 ± 0.78	93.22^a	29.04 ± 1.05	105.37^c	44.32 ± 1.14	163.63^b	0.11 ± 0.03	0.17	0.22 ± 0.01	0.03	0.07 ± 0.03	0.07^a	0.30 ± 0.03	0	0.30 ± 0.05	0.01	0.26 ± 0.03	0.01
	DAB+PB+Ch200	84.67 ± 0.27	32.81	19.737 ± 0.45	114.67	48.71 ± 3.28	159.24^b	0.05 ± 0.03	0.22	0.28 ± 0.04		0.04 ± 0.01	0.11	0.24 ± 0.03	0.06	0.22 ± 0.04	0.07	0.30 ± 0.03	0.03
	Normal	18.72 ± 1.27		15.85 ± 1.39		25.44 ± 0.68		0.09 ± 0.01		0.12 ± 0.03		0.09 ± 0. 01		0.10 ± 0.002		0.09 ± 0.004		0.10 ± 0.003
	PB	25.21 ± 0.31		16.58 ± 0.62		21.88 ± 0.98		0.11 ± 0.002		0.12 ± 0.003		0.11± 0. 003		0.19 ± 0.003		0.18 ± 0.01		0.18 ± 0.003
90	DAB +PB	69.25 ± 0.75		61.42 ± 0.61		91.99 ± 5.20		0.24 ± 0.04		0.27 ± 0.04		0.17± 0. 01		0.36 ± 0.04		0.30 ± 0.01		0.24 ± 0.02
	DAB+PB+Ch30	48.77 ± 3.07	20.48	22.12 ± 0.76	39.30^c	30.95 ± 3.36	61.04^c	0.04 ± 0.01	0.19	0.26 ± 0.05	0.01	0.06 ± 0. 04	0.11^a	0.32 ± 0.07	0.04	0.29 ± 0.04	0.01	0.28 ± 0.04	0.04
	DAB+PB+Ch200	135.74 ± 0.22	-66.49	22.18 ± 0.64	39.24^b	30.49 ± 0.75	61.51^c	0.14 ± 0.06	0.09	0.34 ± 0.02		0.09 ± 0. 04	0.08	0.30 ± 0.04	0.06	0.29 ± 0.02	0.01	0.30 ± 0.04	0.06
	Normal	18.72 ± 1.27		15.85 ± 1.39		25.435 ± 0.68		0.09 ± 0.01		0.12 ± 0.03		0.09 ± 0. 01		0.10 ± 0.002		0.09 ± 0.004		0.10 ± 0.003
	PB	38.63 ± 2.79		44.96 ± 1.49		28.72 ± 0.65		0.14 ± 0.003		0.12 ± 0.01		0.17 ± 0. 002		0.20 ± 0.001		0.15 ± 0.01		0.18 ± 0.001
120	DAB+PB	165.43 ± 1.92		138.65 ± 2.09		274.55 ± 1.08		0.19 ± 0.02		0.31 ± 0.02		0.15 ± 0. 02		0.40 ± 0.07		0.34 ± 0.05		0.29 ± 0.03
	DAB+PB+Ch30	113.04 ± 1.14	52.39^a	89.79 ± 0.48	48.86	92.56 ± 0.18	181.99^c	0.19 ± 0.003	0.001	0.27 ± 0.05	0.04	0.15 ± 0. 003	0.01	0.50 ± 0.05	0.1	0.67 ± 0.09	0.33	0.22 ± 0.05	0.06
	DAB+PB+Ch200	190.25 ± 0.48	-25.82	18.21 ± 0.48	120.45^b	110.51 ± 0.36	160.04^c	0.08 ± 0.01	0.102	0.15 ± 0.06	0.16^a	0.10 ± 0. 01	0.05^a	0.28 ± 0.02	0.12^a	0.16 ± 0.02	0.17	0.24 ± 0.01	0.05

SE= Standard error, a =p < 0.05, b= p < 0.01, c= p < 0.001. Prot. = Protection given by the drug.

Back to article page

ISSN: 2662-7671

Contact us

Submission enquiries: bmccomplementarymedicineandtherapies@biomedcentral.com
General enquiries: ORSupport@springernature.com